A type of keratin L3-11, its preparation method and uses

The preparation of keratin L3-11 through genetic engineering and purification techniques solved the problem of difficult extraction of keratin, achieving efficient preparation and demonstrating various drug application effects.

CN123106867APending Publication Date: 2026-11-17INST OF MATERIA MEDICA CHINESE ACAD OF MEDICAL SCI
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202510625155.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2025-05-15
Publication Date
2026-11-17

AI Technical Summary

Technical Problem

Hard keratin is insoluble in various solvents and resistant to enzymatic hydrolysis, making its extraction and preparation difficult and preventing its widespread and effective utilization.

Method used

Hard keratin L3-11 was prepared by genetic engineering. Escherichia coli or yeast was used as the host cell, and expression was induced using expression vectors such as the pET series. The keratin was then purified by ultrafiltration, dialysis, column chromatography and salting out, and a drug that can be used for antipyretic analgesia, antitussive expectoration and anti-inflammatory purposes was prepared.

Benefits of technology

High yield and high purity of keratin L3-11 were achieved, showing antipyretic, antitussive, expectorant and anti-inflammatory effects, and it has multiple routes of administration and dosage forms.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005403718770000085
    Figure BDA0005403718770000085
  • Figure BDA0005403718770000101
    Figure BDA0005403718770000101
  • Figure BDA0005403718770000111
    Figure BDA0005403718770000111
Patent Text Reader

Abstract

This invention belongs to the field of pharmaceutical technology and provides a sclerokeratin L3-11, its preparation method, and its uses. Specifically, it provides a sclerokeratin L3-11 encoding a nucleic acid molecule, an expression vector, and a host cell; a method for preparing sclerokeratin L3-11; and a pharmaceutical composition containing sclerokeratin L3-11. It also provides the application of this sclerokeratin L3-11, the nucleic acid molecule, the expression vector, the host cell, or the pharmaceutical composition in the preparation of antipyretic, analgesic, antitussive, expectorant, and anti-inflammatory drugs.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention belongs to the field of pharmaceutical technology. It relates to a sclerokeratin L3-11, a nucleic acid molecule encoding sclerokeratin L3-11, an expression vector containing the nucleic acid molecule, a host cell containing the expression vector or whose genome integrates the nucleic acid molecule, a method for preparing sclerokeratin L3-11, and the application of this sclerokeratin in the preparation of antipyretic, analgesic, antitussive, expectorant, and anti-inflammatory drugs. Background Technology

[0002] Keratin belongs to the fibrous structural protein family and is a class of proteins commonly found in animal appendages such as horns, feathers, hooves, and nails. It possesses high mechanical strength and toughness. Keratin is a crucial structural protein in connective tissue, playing a vital role in protecting the body.

[0003] Hard keratin is widely found in organisms and is a renewable resource with great value, but it has not been widely and effectively utilized. The main reason is that hard keratin is insoluble in various solvents, and it is generally more resistant to enzymatic degradation by proteases than other proteins. Therefore, extracting and preparing natural hard keratin is extremely difficult.

[0004] With the rapid development of modern biotechnology such as genomics, proteomics, genetic engineering, and microbial engineering, an increasing number of genes are being discovered. Utilizing protein expression systems to prepare and produce target proteins is an important method for studying the biological functions of genes or proteins. Summary of the Invention

[0005] The technical problem solved by the present invention is to provide a scleroprotein L3-11, a nucleic acid molecule encoding scleroprotein L3-11, an expression vector containing the nucleic acid molecule, a host cell containing the expression vector or the genome integrating the nucleic acid molecule, a method for preparing scleroprotein L3-11, and the application of the above-mentioned scleroprotein L3-11 in the preparation of antipyretic, analgesic, antitussive, expectorant, and anti-inflammatory drugs.

[0006] To solve the technical problem of this invention, the present invention provides the following technical solution:

[0007] The first aspect of the present invention is to provide a hard keratin L3-11, characterized in that the amino acid sequence of the hard keratin L3-11 is as follows:

[0008] (1) The amino acid sequence shown in SEQ ID NO.1 of the sequence listing;

[0009] (2) The amino acid sequence that retains the same biological function as the amino acid sequence shown in SEQ ID NO.1 in the sequence listing, formed by replacing, deleting or adding 1-15 amino acids.

[0010] Furthermore, conventional modifications can be made to scleralin L3-11; or tags for detection or purification can be attached to scleralin L3-11.

[0011] Furthermore, the conventional modifications include acetylation, amidation, oxidation, phosphorylation, methylation, alkylation, formation of disulfide bonds, or cleavage of disulfide bonds. The purification tags include His tags and GST tags.

[0012] The second aspect of the present invention is to provide a nucleic acid molecule encoding the keratin L3-11 described in the first aspect.

[0013] Furthermore, the nucleotide sequence of the nucleic acid molecule is as follows:

[0014] (1) The nucleotide sequence shown in SEQ ID NO.2 in the sequence listing;

[0015] (2) The nucleotide sequence obtained by sequence optimization based on the nucleotide sequence shown in SEQ ID NO.2;

[0016] (3) A nucleotide sequence complementary to the nucleotide sequence in (1) or (2) above.

[0017] A third aspect of the present invention is to provide an expression vector, characterized in that the expression vector contains the nucleic acid molecule described in the second aspect.

[0018] Furthermore, the expression vector can be pET series, pUC series, pQE series, pBV series, pMAL series, etc.; the preferred expression vector is the pET series vector; the most preferred expression vector is pET-28a(+).

[0019] The fourth aspect of the present invention is to provide a host cell, characterized in that the host cell contains the expression vector described in the third aspect or the nucleic acid molecule described in the second aspect is integrated into the genome.

[0020] Furthermore, the host cells include *Escherichia coli* or yeast. Competent host cells can be from the BL21 series, Transetta series, Rosetta series, DH5α series, JM series, Top series, Organami series, Trans1-T1, TG1, TB1; Y11430, MG1003, GS115(AOX1), KM71, SMD1168, etc.; the preferred expression competent cell is BL21(DE3).

[0021] The fifth aspect of the present invention is to provide a method for preparing the hard keratin L3-11 described in the first aspect, characterized by comprising the following steps:

[0022] A. Synthesize the nucleic acid molecule corresponding to the keratin L3-11 described in the first aspect, link the nucleic acid molecule into the corresponding expression vector, transform the expression vector into the host cell, culture the host cell with the expression vector in a fermentation device under certain conditions and induce the expression of keratin L3-11 to obtain a crude protein solution containing keratin L3-11.

[0023] B. The crude protein solution expressed in step A was separated, purified, and dried to obtain keratin L3-11.

[0024] Furthermore, in step A, the host cell is mainly selected from Escherichia coli, the sclerein L3-11 is expressed in Escherichia coli inclusion bodies, and the fermentation equipment includes a shake flask or a fermenter.

[0025] Furthermore, in step A, after inducing the expression of keratin L3-11, impurities can be cleaned with a cleaning agent, and then dissolved in urea solution to obtain a crude protein solution.

[0026] Furthermore, the culture medium in step A can be LB medium, TB medium, SB medium, SOB medium, SOC medium, PDA medium, YPD medium, Bengal red medium, high-salt Czapek's medium, DOBA medium, Michel, and their modified formulations, etc. LB medium is preferred for shake flasks; LB medium and its modified formulations are preferred for fermenters.

[0027] Furthermore, the inducing agent in step A can be IPTG, lactose, arabinose, etc.; preferably IPTG or lactose.

[0028] Further, in step A, the obtained fermentation broth is centrifuged and the supernatant is discarded; the precipitate is suspended in buffer solution, the cells are broken, centrifuged again, and the supernatant is discarded; the precipitate is washed with a cleaning agent and then dissolved in urea solution to obtain a crude keratin L3-11 protein solution.

[0029] The buffer solution is preferably buffer A, and its volume is: fermentation broth volume: buffer A volume = 1~100:1, preferably 10:1;

[0030] The cleaning agent can be urea solution, guanidine hydrochloride solution, Triton, buffer A, etc., preferably urea solution, and most preferably 8M urea solution. The dosage is: fermentation liquid volume: 8M urea volume = 0.2~100:1, preferably 2~15:1.

[0031] Furthermore, in step B, the separation and purification methods include ultrafiltration / microfiltration membrane purification, salting out, column chromatography, and dialysis.

[0032] Furthermore, in step B, the separation and purification methods are as follows:

[0033] (1) The dialysis method involves purifying the crude protein solution obtained in step A by dialysis to obtain the target keratin L3-11 solution. The molecular weight cutoff of the dialysis bag can be 0.5-10 kD, preferably 3.5-10 kD, and most preferably 3.5 kD.

[0034] (2) The ultrafiltration and microfiltration method is to purify the crude protein solution obtained in step A using membrane technology such as ultrafiltration membrane or microfiltration membrane to obtain a concentrated solution of the target keratin L3-11.

[0035] (3) The column chromatography method is to pass the crude protein solution obtained in step A through column chromatography, such as various exchange columns or size exclusion columns, to separate and purify the target hard keratin L3-11.

[0036] Preferred size exclusion columns are dextran gel columns, such as Superdex 30Increase, Superdex 75Increase, Superdex 200Increase, and Superose 6Increase; preferred exchange columns are ion exchange resin columns: anion exchange resin columns, such as HiTrap Q FF, HiTrap Capto Q ImpRes, Capto Q ImpRes, HiTrap Capto Q, HiTrap DEAE, Toyopearl Q-650M, and Toyopearl SuperQ-650M; and cation exchange resin columns, such as HiTrap SP FF, HiTrap Capto SPImpRes, Capto SPImpRes, HiTrap Capto SP, Toyopearl SP-650M, and Toyopearl Super SP-650M.

[0037] The eluent can be a commonly used eluent in the art, such as water or a salt solution, including sodium chloride solution, sodium dihydrogen phosphate solution, disodium hydrogen phosphate solution, sodium acetate, acetic acid, etc.

[0038] (4) The salting-out method is to purify the crude protein solution obtained in step A by salting out to obtain the target keratin L3-11 suspension.

[0039] The salting-out agent can be ammonium sulfate, sodium sulfate, sodium chloride, magnesium chloride, aluminum sulfate, ammonium nitrate, ammonium chloride, magnesium sulfate, etc. The preferred salting-out agent is ammonium sulfate and its aqueous solution. A saturated ammonium sulfate aqueous solution is added to achieve a final ammonium sulfate concentration of 10–50%, preferably 20–30%, and more preferably 25%.

[0040] The salting-out process is performed 1 to 3 times, preferably 2 times.

[0041] After salting out, the precipitate is washed with pure water, and the washing is performed 2 to 5 times, preferably 3 times.

[0042] Furthermore, the target keratin L3-11 solution obtained from step B purification can be freeze-dried or vacuum-dried into dry powder, or the concentrate can be directly spray-dried into dry powder.

[0043] The sixth aspect of the present invention is to provide a pharmaceutical composition, characterized in that the pharmaceutical composition contains the keratin L3-11 described in the first aspect, or the nucleic acid molecule described in the second aspect, or the expression vector described in the third aspect, or the host cell described in the fourth aspect, as well as a pharmaceutically acceptable carrier or excipient.

[0044] The keratin obtained in the above steps of this invention can be freeze-dried or vacuum-dried into dry powder, or the concentrated liquid can be directly spray-dried into dry powder, and then made into various dosage forms.

[0045] This invention relates to a pharmaceutical composition comprising any of the keratin proteins obtained in the above steps and a pharmaceutically acceptable carrier.

[0046] This invention also relates to pharmaceutical compositions containing the sclerokeratin of this invention as an active ingredient and conventional pharmaceutical excipients or adjuvants. Typically, the sclerokeratin of this invention comprises 0.1% to 100.0% of the total weight of the pharmaceutical composition.

[0047] The present invention also provides a pharmaceutical composition comprising a pharmaceutically effective dose of a keratin protein as an active ingredient and a pharmaceutically acceptable carrier.

[0048] The pharmaceutical compositions described in this invention can be prepared according to methods known in the art. For this purpose, if desired, the proteins of this invention can be combined with one or more solid or liquid pharmaceutical excipients and / or adjuvants to formulate suitable administration or dosage forms for use as human or veterinary medicine.

[0049] The sclerokeratin or pharmaceutical composition containing it of the present invention can be administered in unit dose form, and the route of administration can be enteric or non-enteric, such as oral, intramuscular, subcutaneous, nasal, oral mucosa, eye, lung, skin, vagina, peritoneum, rectum, etc., with oral administration being preferred.

[0050] The administration route of the keratin or pharmaceutical composition containing it of the present invention can be by injection. Injection includes intravenous injection, intramuscular injection, subcutaneous injection, intradermal injection, intraperitoneal injection, and acupoint injection.

[0051] Dosage forms can be liquid, solid, or semi-solid. Liquid dosage forms can include solutions (including true solutions and colloidal solutions), emulsions (including oil-in-water, water-in-oil, and double emulsions), suspensions, injections (including aqueous injections, powder injections, and infusions), eye drops, nasal drops, lotions, and liniments. Solid dosage forms can include tablets (including regular tablets, enteric-coated tablets, lozenges, dispersible tablets, chewable tablets, effervescent tablets, and orally disintegrating tablets), capsules (including hard capsules, soft capsules, and enteric-coated capsules), granules, powders, microcapsules, pellets, suppositories, films, patches, aerosols, and sprays; semi-solid dosage forms can include ointments, gels, and pastes.

[0052] The keratin of this invention can be formulated into ordinary preparations, sustained-release preparations, controlled-release preparations, targeted preparations, and various microparticle delivery systems.

[0053] To formulate unit-dose dosage forms into tablets, a wide variety of excipients known in the art can be used, including diluents, binders, wetting agents, disintegrants, lubricants, and flow aids. Diluents can be starch, dextrin, sucrose, glucose, lactose, mannitol, sorbitol, xylitol, microcrystalline cellulose, calcium sulfate, dicalcium phosphate, calcium carbonate, etc.; wetting agents can be water, ethanol, isopropanol, etc.; binders can be starch paste, dextrin, syrup, honey, glucose solution, microcrystalline cellulose, gum arabic paste, gelatin paste, sodium carboxymethyl cellulose, methyl cellulose, hydroxypropyl methyl cellulose, ethyl cellulose, acrylic resin, carbomer, polyvinylpyrrolidone, polyethylene glycol, etc.; disintegrants can be dry starch, microcrystalline cellulose, low-substituted hydroxypropyl cellulose, cross-linked polyvinylpyrrolidone, cross-linked sodium carboxymethyl cellulose, sodium carboxymethyl starch, sodium bicarbonate and citric acid, calcium carbonate, polyoxyethylene sorbitol fatty acid ester, sodium dodecyl sulfonate; lubricants and flow aids can be talc, silica, stearate, tartaric acid, liquid paraffin, polyethylene glycol, etc. Tablets can also be further processed into coated tablets, such as sugar-coated tablets, film-coated tablets, enteric-coated tablets, or bilayer and multilayer tablets.

[0054] To formulate the drug delivery unit into a pellet, a wide variety of carriers known in the art can be used. Examples of carriers include, for instance, diluents and absorbents such as glucose, lactose, starch, cocoa butter, hydrogenated vegetable oil, polyvinylpyrrolidone, polyethylene glycol glycerol laurate, kaolin, talc, etc.; binders such as gum arabic, yellow gum, gelatin, ethanol, honey, liquid sugar, rice paste, or flour paste, etc.; and disintegrants such as agar powder, dried starch, alginate, sodium dodecyl sulfate, methylcellulose, ethylcellulose, etc.

[0055] To formulate the drug delivery unit into a suppository, a wide variety of carriers known in the art can be used. Examples of carriers include, for instance, polyethylene glycol, lecithin, cocoa butter, higher alcohols, esters of higher alcohols, gelatin, semi-synthetic glycerides, etc.

[0056] To encapsulate the drug delivery unit, the active ingredient, the sclerokeratin of the present invention, is mixed with the various carriers described above, and the resulting mixture is placed in a rigid gelatin capsule or a soft capsule. Alternatively, the active ingredient, the sclerokeratin of the present invention, can be formulated as a microcapsule, suspended in an aqueous medium to form a suspension, or filled into a rigid capsule or formulated as an injectable preparation.

[0057] For example, the keratin of this invention can be formulated into injectable preparations, such as solutions, suspension solutions, emulsions, and lyophilized powder injections. These preparations can be aqueous or non-aqueous and may contain one or more pharmacodynamically acceptable carriers, diluents, binders, lubricants, preservatives, surfactants, or dispersants. Diluents may be selected from water, ethanol, polyethylene glycol, 1,3-propanediol, ethoxylated isostearyl alcohol, polyoxyethylene isostearyl alcohol, polyoxyethylene sorbitan fatty acid esters, etc. Furthermore, to prepare isotonic injections, appropriate amounts of sodium chloride, glucose, or glycerol can be added to the injectable formulation. In addition, conventional excipients, buffers, pH adjusters, etc., can also be added. These excipients are commonly used in the art. Furthermore, if necessary, colorants, preservatives, flavorings, tasters, sweeteners, or other materials can be added to the pharmaceutical preparation.

[0058] To achieve the purpose of medication and enhance the therapeutic effect, the keratin or pharmaceutical composition of the present invention can be administered using any known method of administration.

[0059] The dosage of the sclerokeratin pharmaceutical composition of the present invention depends on many factors, such as the nature and severity of the disease to be prevented or treated, the sex, age, weight, personality, and individual response of the patient or animal, the route of administration, the frequency of administration, and the therapeutic purpose. Therefore, the therapeutic dosage of the present invention can vary widely. Generally speaking, the dosage of the pharmaceutical components used in the present invention is well known to those skilled in the art. The actual amount of drug contained in the final formulation of the sclerokeratin composition of the present invention can be appropriately adjusted to achieve the required therapeutic dose and accomplish the preventive or therapeutic purpose of the present invention. The suitable daily dosage range of the sclerokeratin of the present invention is: 0.01–500 mg / kg body weight, preferably 0.5–100 mg / kg body weight, more preferably 1–50 mg / kg body weight, and most preferably 2–30 mg / kg body weight. The above dosage can be administered in a single dose or divided into several doses, such as two, three, or four doses, depending on the clinical experience of the pharmacist and the administration regimen including the use of other treatment methods. The total dose required for each treatment can be divided into multiple doses or administered as a single dose. The protein or pharmaceutical composition of the present invention can be taken alone or in combination with other therapeutic or symptomatic drugs, with dosage adjustments.

[0060] The seventh aspect of the present invention is to provide the use of the keratin L3-11 described in the first aspect, or the nucleic acid molecule described in the second aspect, or the expression vector described in the third aspect, or the host cell described in the fourth aspect, or the pharmaceutical composition described in the sixth aspect in the preparation of an anti-inflammatory drug.

[0061] To achieve the objective of this invention, the following technical solution is adopted. Specifically, the preparation of the hard keratin L3-11 of this invention includes the following steps:

[0062] (1) Synthesize nucleotide sequences and determine their accuracy;

[0063] The preferred nucleotide sequence is shown in SEQ ID No. 2.

[0064] (2) Transfer the nucleotide sequence into the expression vector;

[0065] The expression vector can be pET series, pUC series, pQE series, pBV series, pMAL series, etc.; the preferred expression vector is the pET series vector; the most preferred expression vector is pET-28a(+).

[0066] (3) Transfect the expression vector into the host cell;

[0067] The host cell can be Escherichia coli or yeast; the preferred host cell is Escherichia coli; the competent cells can be BL21 series, Transetta series, Rosetta series, DH5α series, JM series, Top series, Organami series, Trans1-T1, TG1, TB1; Y11430, MG1003, GS115(AOX1), KM71, SMD1168, etc.; the preferred expression competent cell is BL21(DE3).

[0068] (4) Under appropriate conditions, host cells will be fermented and cultured to induce the expression of the target scleralin L3-11;

[0069] Fermentation equipment can be shake flasks or fermentation tanks;

[0070] The culture medium can be LB medium, TB medium, SB medium, SOB medium, SOC medium, PDA medium, YPD medium, Bengal red medium, high-salt Czapek's medium, DOBA medium, koji medium and their modified formulations, etc.; for shake flask fermentation, LB medium and TB medium are preferred, with LB medium being the most preferred; for fermentation tanks, LB medium and its modified formulations are preferred.

[0071] The inducer can be IPTG, lactose, arabinose, etc.; IPTG and lactose are preferred.

[0072] (5) Enrichment of target scleralin L3-11 product;

[0073] The fermentation broth obtained in step (4) is centrifuged and the supernatant is discarded; the precipitate is suspended in buffer solution, the cells are broken, centrifuged again, and the supernatant is discarded; the precipitate is washed with a cleaning agent and then dissolved in urea solution to obtain L3-11 crude protein solution.

[0074] The preferred buffer is buffer A, and its volume is: fermentation broth volume: buffer A Preferred

[0075] The cleaning agent can be urea solution, guanidine hydrochloride solution, Triton, buffer A, etc., preferably urea solution, and most preferably 8M urea solution, with the following dosage: Preferred

[0076] (6) Isolate and purify the target protein L3-11;

[0077] The crude protein solution obtained in step (5) needs to be purified to obtain the target protein L3-11. The purification can be carried out by dialysis, ultrafiltration, microfiltration, or salting out.

[0078] A. The dialysis step involves purifying the crude protein solution obtained in step (5) by dialysis to obtain the target protein L3-11 solution.

[0079] The molecular weight cutoff of the dialysis bag can be 0.5-10kD, the preferred molecular weight cutoff is 3.5-10kD, and the most preferred molecular weight cutoff is 3.5kD.

[0080] B. The ultrafiltration and microfiltration steps involve purifying the crude protein solution obtained in step (5) using membrane technology such as ultrafiltration or microfiltration to obtain a concentrated solution of the target protein L3-11.

[0081] C. The column chromatography step involves passing the crude protein solution obtained in step (5) through column chromatography, such as various exchange columns or size exclusion columns, to separate and purify the target protein L3-11.

[0082] Preferred size exclusion columns are dextran gel columns, such as Superdex 30Increase, Superdex 75Increase, Superdex 200Increase, and Superose 6Increase; preferred exchange columns are ion exchange resin columns: anion exchange resin columns, such as HiTrap Q FF, HiTrap Capto Q ImpRes, Capto Q ImpRes, HiTrap Capto Q, HiTrap DEAE, Toyopearl Q-650M, and Toyopearl SuperQ-650M; and cation exchange resin columns, such as HiTrap SP FF, HiTrap Capto SPImpRes, Capto SPImpRes, HiTrap Capto SP, Toyopearl SP-650M, and Toyopearl Super SP-650M.

[0083] The preferred choice is anion exchange resin column.

[0084] The eluent can be a commonly used eluent in the art, such as water or a salt solution, including sodium chloride solution, sodium dihydrogen phosphate solution, disodium hydrogen phosphate solution, sodium acetate, acetic acid, etc.

[0085] D. The salting-out step involves purifying the crude protein solution obtained in step (5) by salting out to obtain a suspension of the target protein L3-11.

[0086] The salting-out agent can be ammonium sulfate, sodium sulfate, sodium chloride, magnesium chloride, aluminum sulfate, ammonium nitrate, ammonium chloride, magnesium sulfate, etc. The preferred salting-out agent is ammonium sulfate and its aqueous solution. A saturated ammonium sulfate aqueous solution is added to achieve a final ammonium sulfate concentration of 10–50%, preferably 20–30%, and more preferably 25%.

[0087] The salting-out process is performed 1 to 3 times, preferably 2 times.

[0088] After salting out, the precipitate is washed with pure water, and the washing is performed 2 to 5 times, preferably 3 times.

[0089] The target protein L3-11 solution obtained from purification steps A to D can be freeze-dried or vacuum-dried into dry powder, or the concentrated solution can be directly spray-dried into dry powder.

[0090] Beneficial technical effects of the present invention:

[0091] 1. The protein of this invention is a hard keratin obtained for the first time, and the preparation method of this invention has the characteristics of high yield and high sample purity.

[0092] 2. This invention demonstrates, through a pharmacodynamic study of sclerokeratin L3-11 on a lipopolysaccharide-induced fever model in SD rats, that sclerokeratin L3-11 (10 mg / kg) can reduce the increase in body temperature in the model animals 6 hours after modeling.

[0093] 3. This invention demonstrates, through a pharmacodynamic study of sclerokeratin L3-11 on the antitussive effect of ammonia-induced cough in mice, that sclerokeratin L3-11 (20 mg / kg, 50 mg / kg) can prolong the cough latency period and reduce the frequency of coughs, thus exhibiting an antitussive effect.

[0094] 4. This invention demonstrates, through a pharmacodynamic study of sclerokeratin L3-11 on expectoration in mice using the phenol red excretion method, that sclerokeratin L3-11 (20 mg / kg, 50 mg / kg) has significant expectorant effects at both dosages.

[0095] 5. This invention demonstrates, through pharmacodynamic studies of sclerokeratin L3-11 on a croton oil-induced mouse ear swelling model, that sclerokeratin L3-11 (10 mg / kg, 20 mg / kg, and 40 mg / kg) can reduce ear swelling in mice and has anti-inflammatory effects. Attached Figure Description

[0096] Figure 1 Effects of dacetin L3-11 on a lipopolysaccharide-induced fever model in rats (compared to the normal control group). ** p<0.01; compared with the model group, # p<0.05, ## p<0.01);

[0097] Figure 2 Effect of sclerein L3-11 on the latency of ammonia-induced cough suppression in mice (left); Effect of sclerein L3-11 on the number of coughs in ammonia-induced cough suppression in mice (right) (compared with the solvent control group). * p<0.05, ** p<0.01);

[0098] Figure 3 Effect of dacron L3-11 on phenol red excretion in mouse expectorant assay (compared to solvent control group). * p<0.05, ** p<0.01);

[0099] Figure 4 Effects of keratin L3-11 on croton oil-induced mouse ear swelling model (compared to the model group), *** P<0.001);

[0100] Figure 5 Analysis of keratin L3-11 reduced SDS-polyacrylamide gel electrophoresis (SDS-PAGE), (M: protein molecular weight standard; S: protein L3-11);

[0101] Figure 6 The molecular weight of keratin L3-11 was determined by ESI-MS.

[0102] Figure 7 A schematic diagram of the keratin L3-11 plasmid. Detailed Implementation

[0103] The following examples and pharmacological activity test cases are used to further illustrate the present invention, but they do not imply any limitation on the present invention.

[0104] Unless otherwise specified, the experimental methods used in the following examples and pharmacological activity test cases are conventional methods; unless otherwise specified, the experimental materials used were purchased from conventional biochemical reagent companies.

[0105] Example 1: Preparation of crude keratin L3-11 solution A (LB medium) by shake-flask fermentation

[0106] The nucleotide sequence shown in SEQ ID No. 2 was synthesized and transformed into the pET-28a(+) vector; sequencing confirmed that the expression vector contained the correct sequence was obtained; the expression vector was transfected into BL21(DE3) cells to obtain competent host cells containing the target nucleotide sequence. The cells were added to LB medium and cultured in a shaker at 37°C and 220 rpm for 1 hour to obtain the recombinant strain.

[0107] Streaking of the recombinant strain onto LB agar plates containing Kanamycin, and incubating the plates upside down in a 37°C incubator overnight for 16 hours.

[0108] Prepare 400ml LB medium and dispense it into two 200ml bottles. Add Kanamycin (final concentration 50μg / ml) to each 200ml LB medium bottle. Take a single colony from the plate and add it to the LB medium. Incubate overnight on a shaker at 37℃ and 220rpm to obtain the seed culture.

[0109] Prepare 4.4 LLB medium, aliquoting it into 22 bottles, 200 ml per bottle. Add Kanamycin (final concentration 50 μg / ml) to each 200 ml bottle of LB medium, then add 2 ml of seed culture. Incubate in a shaker at 37°C and 220 rpm for 2-3 hours. Monitor OD 600; when OD 600 reaches approximately 1.0, add the inducer and induce protein expression in a shaker. The induction conditions are selected from the table below.

[0110]

[0111]

[0112] Combine the bacterial cultures from each bottle, centrifuge at 7000 rpm for 5 minutes, sterilize the supernatant and discard it; resuspend the precipitate in approximately 3 L of buffer solution, filter through an 80-100 mesh sieve, and disrupt the filtrate using a high-pressure homogenizer at 800-1000 bar, twice, 2 minutes each time. Centrifuge the disrupted bacterial culture at 7000 rpm for 30 minutes, discard the supernatant, and obtain the precipitate (i.e., inclusion bodies). Wash the precipitate twice successively with buffer solution, 1M urea solution, and 2M urea solution, centrifuge, and discard the supernatant. Dissolve the precipitate in 1 L of 8M urea solution to obtain crude protein solution A.

[0113] Structure confirmation of duracin L3-11:

[0114] 1. Analysis by reduced SDS-polyacrylamide gel electrophoresis (SDS-PAGE)

[0115] Instrument: Protein electrophoresis analyzer (Bio-Red).

[0116] Methods and Results: The sclerokeratin L3-11 solution was analyzed by reducing SDS-PAGE with a separating gel concentration of 15% and stained with Coomassie Brilliant Blue R250. The molecular weight of the sclerokeratin L3-11 band was around 15 kDa.

[0117] 2. Full-series protein analysis based on LC-MS / MS

[0118] Main ingredients: ammonium bicarbonate, dithiothreitol (DTT), iodoacetamide (IAA), trypsin;

[0119] Main instrument: Thermo Q Exative Hybrid Quadrupole Orbitrap Mass Spectrometer.

[0120] Methods and Results: Recombinant scleroprotein L3-11 was pretreated with dissolution, displacement, reductive alkylation, and trypsin to obtain enzymatically digested peptides. The enzymatically digested peptide solutions were analyzed by liquid chromatography-tandem mass spectrometry. The raw mass spectrometry data were analyzed by searching the protein database using PEAKS (11.0), and the identification results confirmed that it was consistent with the target sequence SEQ ID No. 1.

[0121] Example 2: Pharmacological test of dacetin L3-11 (protein from Example 1) on LPS-induced fever model in SD rats.

[0122] Animals: Male SD rats, 230-260g (Huafukang Biotechnology Co., Ltd.);

[0123] Drugs: Lipopolysaccharide (SIGMAL-2880), Aspirin (SIGMAA2093), Protein L3-11;

[0124] Instruments: Electronic balance (SARTORIUSBP121S), electronic thermometer (CITIZEN CT-513W).

[0125] Experimental Groups:

[0126] Normal control group (N=8);

[0127] Lipopolysaccharide-induced fever model group (N=8);

[0128] Positive drug group: Aspirin 300mg / kg (N=8);

[0129] L3-11 10mg / kg group (N=8);

[0130] L3-11 50mg / kg group (N=8).

[0131] Experimental methods:

[0132] Preparation of experimental animals: After acclimatizing to the experimental environment (temperature 22℃±2℃, relative humidity 50%±2%) for one day, the experimental animals underwent pre-acclimatization rectal temperature measurements at 8:00 AM and 3:00 PM. The animals were fasted for 12 hours prior to the experiment, but water was permitted. Before measuring rectal temperature, the animals were emptied of their feces. Before each measurement, the electronic thermometer probe was coated with Vaseline and inserted 2 cm into the rat's rectum (a mark can be made at the 2 cm point to ensure consistent insertion depth each time). The temperature value was recorded after the reading stabilized.

[0133] Intraperitoneal injection of lipopolysaccharide to establish a rat fever model: Before modeling, rat body temperature was measured, and qualified rats with a body temperature of 36.2-37.3℃ were selected and randomly divided into groups of 8 rats each. Rats were administered aspirin or different doses of protein L3-11 orally, followed immediately by intraperitoneal injection of lipopolysaccharide (20 μg / kg, 2 ml / kg). The normal control group received an equal volume of physiological saline intraperitoneally. Body temperature was monitored starting 2 hours later, every 2 hours for a total of 8 hours.

[0134] Data processing:

[0135] Based on the body temperature values ​​measured at various time points on the day of the experiment, the mean, standard deviation, and standard error of body temperature of rats in each group were calculated. The data of each group were compared between groups using the t-test, and p < 0.05 was considered to be statistically significant.

[0136] Experimental results:

[0137] Animals were orally administered aspirin (300 mg / kg) and protein L3-11 (10 mg / kg and 50 mg / kg), followed immediately by an intraperitoneal injection of 20 μg / kg lipopolysaccharide to induce a model. Body temperature was monitored at 2, 4, 6, and 8 hours post-modeling. Results are shown in Table 1 and [Table data missing]. Figure 1 .

[0138] Table 1. Effects of the test drug on the LPS-induced fever model in rats

[0139]

[0140]

[0141] (Compared with the normal control group, ** p<0.01; compared with the model group, # p<0.05, ## p<0.01)

[0142] Experimental conclusion:

[0143] Animals were given oral aspirin (300 mg / kg) and protein L3-11 (10 mg / kg and 50 mg / kg), followed immediately by intraperitoneal injection of 20 μg / kg lipopolysaccharide to establish the model. Animal body temperature was monitored at 2, 4, 6 and 8 hours after modeling.

[0144] The results show:

[0145] 1) The body temperature of rats in the model group increased significantly at 2, 4, 6 and 8 hours after modeling, which was statistically different from that in the normal group (p<0.05). The model was successfully established and is stable and reliable.

[0146] 2) The positive control drug aspirin group effectively inhibited the rise in body temperature of model rats at 2, 4, 6 and 8 hours after modeling. Compared with the model group, p<0.05, which showed statistical difference. The positive control drug aspirin showed stable performance.

[0147] 3) Protein L3-11 at 10 mg / kg at 6 and 8 hours after modeling, and L3-11 at 50 mg / kg at 2 and 6 hours after modeling, can effectively inhibit the rise in body temperature of model rats. Compared with the model group, p<0.05, indicating statistical difference.

[0148] Experiment 3: Efficacy test of dacetin L3-11 (protein from Example 1) in suppressing cough in mice using ammonia-induced cough method

[0149] Animals: Male ICR mice, 22-24g;

[0150] Drugs and reagents: Dextromethorphan hydrobromide, ammonia, protein L3-11;

[0151] Instruments: Compressor atomizer (403T type), balance (XS105DU type).

[0152] Experimental Groups:

[0153] Solvent control group (N=8);

[0154] Positive drug group: Dextromethorphan hydrobromide 15 mg / kg (N=8);

[0155] L3-11 20mg / kg group (N=8);

[0156] L3-11 50mg / kg group (N=8).

[0157] Experimental methods:

[0158] Model preparation and administration: The mice were orally administered dextromethorphan and different doses of protein L3-11 (10 ml / kg) according to the group. The solvent control group was given an equal volume of distilled water. After 1 hour, the mice were placed in a sealed box and nebulized with 10% ammonia for 10 seconds. The cough latency and the number of coughs within 2 minutes were then observed and recorded.

[0159] Data processing:

[0160] The time points for oral administration, nebulization, cough latency, and the number of coughs within 2 minutes were recorded. Cough latency refers to the number of seconds from the start of ammonia nebulization to the onset of cough. Coughing in mice was characterized by abdominal muscle contraction (chest retraction) and wide-open mouth. The mean and standard error of each group were calculated, and a t-test was applied. The model group was compared with other groups; p < 0.05 was considered statistically significant.

[0161] Experimental results:

[0162] Mice were given dextromethorphan (15 mg / kg) and different doses of protein L3-11 (20 mg / kg, 50 mg / kg) in advance. One hour later, they were placed in a sealed box and nebulized with 10% ammonia for 10 seconds. The cough latency and the number of coughs within 2 minutes were then observed and recorded. The results are shown in Table 2 and [Table data missing]. Figure 2 .

[0163] Table 2. Antitussive efficacy of the test drug on mice induced by ammonia water cough (X±SEM)

[0164]

[0165] (Compared with the solvent control group, * p<0.05, ** p<0.01)

[0166] Experimental conclusion:

[0167] 1) The experimental results showed that the dextromethorphan hydrobromide group had a significant improvement in the latency period and the number of coughs compared with the solvent control group (p<0.05), which was statistically significant.

[0168] 2) The L3-11 20mg / kg group and the L3-11 50mg / kg group showed statistically significant differences in cough latency and cough frequency compared with the solvent control group (p<0.05).

[0169] Experiment 4: Pharmacological effect of duracin L3-11 (protein from Example 1) on expectoration by phenol red excretion in mice.

[0170] Animals: Male ICR mice, 21-23g;

[0171] Drugs and reagents: Ambroxol hydrochloride tablets, phenol red, sodium bicarbonate, protein L3-11;

[0172] Instruments: Centrifuge (Sigma-3K15), balance (XS105DU), ELISA reader (BIO-TEK).

[0173] Experimental Groups:

[0174] Solvent control group (N=8);

[0175] Positive drug group: Ambroxol 30 mg / kg (N=8);

[0176] L3-11 20mg / kg group (N=8);

[0177] L3-11 50mg / kg group (N=8).

[0178] Experimental methods:

[0179] Model preparation and drug administration: Animals were fasted for 16 hours before the experiment but allowed free access to water. They were orally administered ambroxol and different doses of protein L3-11 (10 ml / kg) according to their groups. The solvent control group received an equal volume of distilled water. One hour later, mice were intraperitoneally injected with 2.5% phenol red solution. Thirty minutes later, the mice were euthanized by cervical dislocation. The trachea, from below the thyroid cartilage to the pretracheal branch, was removed. The trachea was placed in 3 ml of 5% NaHCO3 solution and allowed to stand for 3 hours. One ml of the supernatant was collected, centrifuged at 3000 rpm for 5 minutes, and the absorbance was measured and recorded at 546 nm. The excretion of phenol red was calculated based on the phenol red standard curve.

[0180] Data processing:

[0181] The time points for oral administration, intraperitoneal injection of 2.5% phenol red solution, and tracheal aspiration were recorded separately. The absorbance of each group of samples was measured at 546 nm using an ELISA reader, and the excretion of phenol red was calculated based on the standard curve of phenol red. The mean and standard error of each group's data were calculated, and a t-test was applied. The solvent control group was compared with other groups, and p < 0.05 was considered statistically significant.

[0182] Experimental results:

[0183] Mice were administered ambroxol (30 mg / kg) and different doses of protein L3-11 (20 mg / kg, 50 mg / kg). One hour later, they were intraperitoneally injected with 2.5% phenol red solution. Thirty minutes later, the mice were euthanized by cervical dislocation. The trachea, from below the thyroid cartilage to the segment before the tracheal branch, was harvested. The trachea was placed in 3 ml of 5% NaHCO3 solution and allowed to stand for 3 hours. One ml of the supernatant was collected, centrifuged at 3000 rpm for 5 minutes, and the absorbance was measured and recorded at 546 nm. The excretion of phenol red was calculated based on the standard curve of phenol red. The results are shown in Table 3. Figure 3 .

[0184] Table 3. Expectorant efficacy of the test drug against mice using the phenol red excretion method (X±SEM)

[0185]

[0186]

[0187] (Compared with the solvent control group, * p<0.05, ** p<0.01)

[0188] Experimental conclusion:

[0189] 1) The experimental results showed that compared with the solvent control group, the excretion of phenol red in the 30mg / kg group of ambroxol was significantly increased (p<0.05), which was statistically significant.

[0190] 2) Compared with the solvent control group, the excretion of phenol red in the L3-11 20mg / kg group and the L3-11 50mg / kg group was significantly increased (p<0.05), which was statistically significant.

[0191] Experiment 5: Efficacy test of dacetin L3-11 (protein from Example 1) in a croton oil-induced mouse ear swelling model

[0192] Animals: 20-23g of male Kunming mice;

[0193] Medicines and reagents: Croton oil, physiological saline, protein L3-11;

[0194] Instruments: electronic balance, 8mm hole punch, surgical scissors, forceps;

[0195] Experimental Groups:

[0196] Solvent control group;

[0197] Positive control group: Dexamethasone 10 mg / kg;

[0198] Protein L3-11 10mg / kg group;

[0199] Protein L3-11 20mg / kg group;

[0200] Protein L3-11 40mg / kg group.

[0201] Experimental methods:

[0202] Model preparation and drug administration: Experimental animals were acclimatized overnight in the animal room. They were allowed free access to food and water before the experiment and were randomly divided into 5 groups, with at least 10 animals in each group, and marked. Different doses of protein L3-11 were administered subcutaneously according to the groups (dose volumes of 10 mg / kg, 20 mg / kg, and 40 mg / kg). The solvent control group received an equal volume of physiological saline. Thirty minutes after drug administration, 50 μL of 2% croton oil was applied to both the anterior and posterior surfaces of the left ear of each mouse. Four hours later, the mice were euthanized by dislocation, and both ears were cut off along the auricular baseline. Round ear pieces were punched out from the same location on both ears using an 8 mm diameter punch.

[0203] Data processing:

[0204] Weigh the difference in weight between the left and right ears, and calculate the degree of ear swelling (ear swelling = weight of left ear piece - weight of right ear piece) and the ear swelling inhibition rate [(average ear swelling in the model group - ear swelling in the treatment group) / average ear swelling in the model group × 100%]. Compared with the model group, p *** <0.001.

[0205] Experimental results:

[0206] Table 4 shows the degree of ear swelling and the inhibition rate of ear swelling in mice after administration of dexamethasone (10 mg / kg) and protein L3-11 at doses of 10 mg / kg, 20 mg / kg, and 40 mg / kg. Compared with the solvent control group, all three dose groups of protein L3-11 significantly reduced ear swelling in mice, which was statistically significant. The results are shown in Table 4. Figure 4 .

[0207] Table 4. Effects of protein L3-11 on croton oil-induced ear inflammation in mice (Mean ± SD, n = 10)

[0208]

[0209] (Compared with the solvent control group, *** p<0.001).

Claims

1. A keratin L3-11, characterized in that... The amino acid sequence of the active peptide is as shown in SEQ ID No.

1.

2. The keratin L3-11 according to claim 1, characterized in that... Amino acid sequences with essentially the same biological function are formed by shifting, substituting, deleting, or adding 1-12 amino acids.

3. The keratin L3-11 according to any one of claims 1 or 2, characterized in that... In SEQ ID Based on the No.1 amino acid sequence, conventional modifications can be made, including acetylation, amidation, oxidation, phosphorylation, methylation, alkylation, biotinylation, polyethylene glycol modification, and the formation or breaking of disulfide bonds.

4. A nucleic acid molecule encoding the keratin L3-11 of any one of claims 1-3.

5. The nucleic acid molecule according to claim 4, characterized in that, The nucleotide sequence of the nucleic acid molecule is as follows: (1) The nucleotide sequence shown in SEQ ID NO.2 in the sequence listing; (2) The nucleotide sequence obtained by sequence optimization based on the nucleotide sequence shown in SEQ ID NO.2; (3) A nucleotide sequence complementary to the nucleotide sequence in (1) or (2) above.

6. An expression carrier, characterized in that, The expression vector contains the nucleic acid molecule as described in any one of claims 4-5.

7. A host cell, characterized in that, The host cell contains the expression vector of claim 6 or the genome integrated with any one of claims 4-5.

8. The host cell according to claim 7, characterized in that, The host cells include bacteria, yeast, streptomyces, plant cells, or insect cells.

9. The host cell according to claim 8, characterized in that, The bacteria mentioned include Escherichia coli.

10. A method for preparing the hard keratin L3-11 according to any one of claims 1-3, characterized in that, Includes the following steps: A. Synthesize the nucleic acid molecule of keratin L3-11 as described in any one of claims 1-3, link the nucleic acid molecule into the corresponding expression vector, transform the expression vector into a host cell, culture the host cell with the expression vector in a fermentation device under certain conditions and induce the expression of keratin L3-11, and obtain a crude protein solution containing keratin L3-11. B. The crude protein solution obtained in step A is separated, purified, and dried to obtain keratin L3-11.

11. The method according to claim 10, characterized in that, In step A, the host cell is Escherichia coli, and the fermentation equipment includes, but is not limited to, shake flasks or fermenters.

12. The method according to claim 10, characterized in that, In step A, after inducing the expression of keratin L3-11, impurities can be washed away with a cleaning agent, and the crude protein solution can be obtained by dissolving it in a solution.

13. The method according to claim 10, characterized in that, In step B, the separation and purification methods include ultrafiltration / microfiltration membrane purification, salting out, column chromatography, and dialysis.

14. A pharmaceutical composition, characterized in that, The pharmaceutical composition comprises keratin L3-11 as described in any one of claims 1 to 3 and a pharmaceutically acceptable carrier or excipient.

15. The use of the keratin L3-11 according to any one of claims 1 to 3, or the nucleic acid molecule according to any one of claims 4 to 5, or the expression vector according to claim 6, or the host cell according to claims 7 to 9, or the pharmaceutical composition according to claim 14 in the preparation of antipyretic, analgesic, antitussive, expectorant, and anti-inflammatory drugs.